The estimated Net Worth of Jaakko Taneli Jouhikainen is at least $1.49 Milione dollars as of 4 April 2019. Jaakko Jouhikainen owns over 25,000 units of Savara Inc stock worth over $723,898 and over the last 7 years Jaakko sold SVRA stock worth over $761,860.
Sign up
Jaakko Jouhikainen SVRA stock SEC Form 4 insiders trading
Jaakko has made over 4 trades of the Savara Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Jaakko sold 25,000 units of SVRA stock worth $225,750 on 4 April 2019.
The largest trade Jaakko's ever made was selling 25,000 units of Savara Inc stock on 4 April 2019 worth over $225,750. On average, Jaakko trades about 13,043 units every 111 days since 2017. As of 4 April 2019 Jaakko still owns at least 167,569 units of Savara Inc stock.
You can see the complete history of Jaakko Jouhikainen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jaakko Jouhikainen's mailing address?
Jaakko's mailing address filed with the SEC is 6836 BEE CAVE ROAD, BUILDING III, SUITE 200, AUSTIN, TX, 78746.
Insiders trading at Savara Inc
Over the last 7 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
What does Savara Inc do?
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
What does Savara Inc's logo look like?
Complete history of Jaakko Jouhikainen stock trades at Savara Inc
Savara Inc executives and stock owners
Savara Inc executives and other stock owners filed with the SEC include:
-
Dr. Badrul A. Chowdhury M.D., Ph.D.,
Chief Medical Officer -
David Lowrance,
Chief Financial Officer, Secretary -
David L. Lowrance,
CFO & Sec. -
Ricky Sun,
Independent Director -
Annigje van Es-Johansson,
Independent Director -
Badrul Chowdhury,
Chief Medical Officer -
Anne Erickson,
IR Contact Officer -
David Ramsay,
Independent Director -
Matthew Pauls,
Chairman of the Board, Interim Chief Executive Officer -
Joseph McCracken,
Independent Director -
Richard Hawkins,
Independent Director -
Nevan Elam,
Independent Director -
Dr. Peter Clarke Ph.D.,
Exec. VP of Global Technical Operations -
Charles LaPree,
Sr. VP of Global Regulatory Affairs & Quality Assurance -
Brian Maurer,
Head of Clinical Operations -
Dr. Dhaval Desai M.D.,
Head of Clinical Devel. -
Kate McCabe,
Sr. VP of Legal Affairs -
Robert N Neville,
Chief Executive Officer -
Yuri Pikover,
Director -
Jaakko Taneli Jouhikainen,
See Remarks -
Es Johansson An Van,
Director -
Forest Baskett,
10% owner -
Equity Opportunities 17, Ll...,
-
Rick Yang,
10% owner -
Paul Edward Walker,
10% owner -
Scott D Sandell,
10% owner -
Edward T Mathers,
10% owner -
Mohamad Makhzoumi,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ali Behbahani,
10% owner -
Raymond Dennis Pratt,
Chief Medical Officer -
Robert Matthew Lutz,
Chief Operating Officer